UE 2024 - PEEU Von der Leyen names new EU CommissionersEuropean Commission President Ursula von der Leyen has revealed her nominees for new commissioners to lead the bloc for the next term from 2024 to 2029. more ➔
ImmunOs Therapeutics AG FinancingImmunOs Therapeutics AG raises US$11m in S...Swiss cancer and auto-immunity specialist ImmunOs Therapeutics AG has closed a Series C financing round of US$11m led by existing investors Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners … more ➔
BIOCOM Interrelations GmbHContract biomanufacturingRichter-Helm Biologics triples production...After three and a half years of construction, the CDMO Richter Biologics has inaugurated its new multipurpose production facility that triples the CDMO’s capacity for the bacterial production of pDNA, … more ➔
Phoremost LtdProtein DegradersPhoremost reports Series B extensionBritish protein degrader specialist PhoreMost Ltd has extended its €33m Series B financing to $50M and plans to advance its oncology and inflammation degrader programmes. more ➔
FinancingFunding for green insecticidesAgri-biotech SOLASTA Bio Ltd. has raised US$14m in a Series A funding round led by Forbion. With the money, the UK company will advance its first-of-a kind peptide-based bioinsecticide. more ➔
AstraZenecaPhase IIIAZ’s lung cancer drug disappointsA Phase III trial evaluating AstraZeneca and Daiichi Sankyo’s potential “blockbuster” lung cancer drug Dato-DXd showed no significant improvement over standard chemotherapy. Investors reacted quickly: … more ➔
King's CollegeAllergyEpsilogen Ltd completes £12.5m Series B e...A new £12.5m Series B expansion brings Elipsogen Ltd’s total Series B funds raised to £43.25 million. The IgE antibody specialist will use the roceeds to support the delivery of clinical Proof of Concept … more ➔
Hayo Therapeutics SAObesitySwiss RNA maker Haya in huge licence dealSwiss HAYA Therapeutics SA has inked a US$1bn biobuck deal with pharma giant Eli Lilly to discover new lncRNA targets in obesity and related metabolic conditions. more ➔
Innerstream - wikimedia.orgMultiple sclerosisRoche with good interim clinical resultsRoche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression after one year in patients with relapsing multiple sclerosis more ➔
Individor plcPartnershipIndividor set to waive AEF0117 licence aft...Following the failure of Aelis Farma’s lead candidate AEF0117 in a Phase IIb study in patients with cannabis use disorder or cannabis-induced psychosis, Individor plc has stated that it will not exercise … more ➔
UE 2024 - PE
ImmunOs Therapeutics AG 
BIOCOM Interrelations GmbH
Phoremost Ltd
AstraZeneca
King's College
Hayo Therapeutics SA
Innerstream - wikimedia.org
Individor plc